NCT03309566View on ClinicalTrials.gov

Bioequivalence Study of Two Formulatiosns With the Asscociaton of Efavirenz, Emtricitabine and Tenofovir

PHASE4CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 4, 2016

Primary Completion Date

February 28, 2017

Study Completion Date

February 28, 2017

Conditions
Healthy
Interventions
DRUG

Efavirenz, tenofovir disoproxil fumarate and emtricitabine

Two period administration of a formulation containing a combination of efavirenz 600 mg, emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg.

Trial Locations (1)

3102

DominguezLab, Paraná

Sponsors
All Listed Sponsors
lead

Laboratorio Elea Phoenix S.A.

INDUSTRY